RxDoctor Payments Data

Lawrence Kline, OD

Optometrist · Prospect, CTNPI 1245444546

Payments from drug & device makers

$3,577in general payments, 2019–2025

Across 162 payments — averaging $22.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$526
  • Sun Pharmaceutical Industries Inc.$474
  • Bausch & Lomb Americas Inc.$361
  • Coopervision Inc.$349
  • Novartis$285
  • AbbVie$214
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,577100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,577 in reported general payments places this provider in the 85th percentile of 574 optometrist providers in Connecticut.

See all optometrist providers in Connecticut

Medicare billing

Part B allowed, 2024
$38,620
Medicare patients
92
Services billed
636

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine37$26,339
XdemvyLotilaner11$20,573
VyzultaLatanoprostene Bunod33$18,601
LumiganBimatoprost27$14,389
RocklatanNetarsudil Mesylat/Latanoprost32$11,746
MieboPerfluorohexyloctane/Pf14$10,928
XiidraLifitegrast14$9,873
SimbrinzaBrinzolamide/Brimonidine Tart12$4,342
CombiganBrimonidine Tartrate/Timolol12$2,347
Timolol Maleate11$299
Latanoprost11$38

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$214$43,07676 claims
Bausch & Lomb Americas Inc.Vyzulta, Miebo, Xiidra$361$39,40261 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$162$20,57311 claims
Aerie Pharmaceuticals, Inc.Rocklatan$17$11,74632 claims
AlconSimbrinza$526$4,34212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 574 optometrist providers in Connecticut.

Other optometrist in Prospect

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →